Immune-related adverse events (irAEs) is the collective term used to describe the side effects that arise in response to activation of the immune system by immunotherapies. As this class of cancer treatment yields undisputed...
The FDA expanded the use of pembrolizumab to treat certain patients with a rare, aggressive type of skin cancer called Merkel cell carcinoma.
Back for the new year, here are the editors’ selections for the January issues of the eight scientific journals published by the American Association for Cancer Research (AACR). Featured research highlights a wide variety...
The FDA approved a new molecularly targeted therapeutic called gilteritinib for treating certain patients with acute myeloid leukemia (AML).
The FDA approved the first molecularly targeted therapeutic for use based on a tumor biomarker rather than where the cancer originates.
The FDA approved two separate molecularly targeted therapeutics for treating patients aged 75 or older with acute myeloid leukemia (AML).
The FDA expanded the use of the immunotherapy pembrolizumab to include the treatment of certain patients with liver cancer.
The FDA approved a molecularly targeted therapeutic for treating certain patients with metastatic non-small cell lung cancer.
In the final weeks of 2018, the U.S. Food and Drug Administration (FDA) announced three approvals of anticancer therapeutics. These decisions brought the total number of new anticancer therapeutics approved by the FDA in 2018 to 18, a record in recent years. In addition, the agency approved expanding the use of 10 previously approved anticancer therapeutics to include new types of cancer in 2018.
The FDA approved a targeted therapeutic for treating patients with breast cancer that tests positive for a cancer-associated BRCA1 or BRCA2 mutations.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More